[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1139 Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy

Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster I
Saturday, December 7, 2013, 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)

Petra MG Erkens, PhD1*, Gregory J Fermann, MD, FACEP2*, Martin H Prins, MD3*, Philip S Wells, MD, MSc4, Akos F Pap, MSc5* and Anthonie WA Lensing, MD5*

1Maastricht University, Maastricht, Netherlands
2Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH
3Maastricht University Medical Centre, Maastricht, Netherlands
4Ottawa Hospital Research Institute, Ottawa, ON, Canada
5Bayer HealthCare AG, Wuppertal, Germany

Background: The Pulmonary Embolism Severity Index (PESI) has been validated in the setting of standard treatment of pulmonary embolism with initial low molecular weight heparin followed by vitamin K antagonists. We evaluated the proposed simplified PESI in a large, phase III randomized trial involving patients with symptomatic pulmonary embolism with or without deep vein thrombosis, who were treated with rivaroxaban or standard therapy.

 

Methods: The EINSTEIN PE study was an open-label, randomized, phase III study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin overlapping with and followed by a vitamin K antagonist (warfarin or acenocoumarol, target international normalized ratio 2.0–3.0) for 3, 6, or 12 months in patients with acute, symptomatic pulmonary embolism. At baseline, the simplified PESI score was assessed, with 1 point each assigned for age >80 years, history of cancer, chronic cardiopulmonary disease, heart beat ≥110 beats per minute, systolic blood pressure <100 mm Hg, and arterial oxyhemoglobin saturation <90%. Recurrent venous thromboembolism, fatal pulmonary embolism, all-cause mortality, and major bleeding at 7 days, 14 days, 30 days, 90 days, and at the end of the full intended treatment period were related to the simplified PESI score.

 

Results: It was possible to calculate the simplified PESI score in 4831 of the 4832 included patients, of whom 2589 (53.6%) had a PESI score of 0; 1775 (36.7%) had a score of 1; and 467 (9.7%) had a score of 2 or 3. No patient had a simplified PESI score greater than 3. Incidences of outcomes in relation to time period, simplified PESI score and treatment are presented in the following table.

 

Conclusions: Among patients with a simplified PESI score of 0 or 1, major clinical outcome events were rare during the first 30 days of treatment and were similar in patients treated with rivaroxaban or standard therapy. Patients with a simplified PESI score of 2 or more in both treatment groups had more frequent adverse outcomes both initially and in the long term.

Table. Incidences of outcomes in relation to time period, simplified PESI score, and treatment

 

Outcome/
time period

Treatment

Up to day 7

Up to day 14

Up to day 30

Up to day 90

Full period

PESI score

0

1

≥2

0

1

≥2

0

1

≥2

0

1

≥2

0

1

≥2

Recurrent VTE, %

Rivaroxaban

0.4

0.2

1.6

0.6

0.7

1.6

0.8

1.0

1.6

1.4

1.4

2.5

1.9

1.8

3.7

Standard

0.3

0.4

1.3

0.5

0.7

2.2

0.7

1.1

3.6

1.1

1.4

4.5

1.4

1.8

4.9

Fatal PE, %

Rivaroxaban

0

0

0.4

0

0.1

0.4

0

0.2

0.4

0.2

0.2

1.2

0.2

0.3

2.0

Standard

<0.1

0.1

0.9

0.2

0.1

0.9

0.2

0.2

0.9

0.2

0.2

0.9

0.2

0.2

1.3

All-cause mortality, %

Rivaroxaban

0

0.1

1.2

0

0.1

0.6

0

0.8

4.1

0.5

1.4

5.7

0.6

2.8

9.8

Standard

<0.1

0.1

1.8

0.2

0.2

2.2

0.2

0.8

3.1

0.3

1.3

6.3

0.5

2.2

10.8

Major bleeding, %

Rivaroxaban

0.3

0

0.8

0.5

0.1

0.8

0.5

0.3

0.8

0.7

0.7

1.2

0.9

1.1

2.1

Standard

0.2

0.6

1.4

0.5

0.9

1.8

0.7

1.1

3.2

0.8

1.8

3.6

1.2

2.8

5.4

PE, pulmonary embolism; VTE, venous thromboembolism.

 

Disclosures: Fermann: Novartis: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Radiometer: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Cubist: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Cardiorentis: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity’s Board of Directors or advisory committees, Research Funding. Prins: Bayer HealthCare: Consultancy; Sanofi-aventis: Consultancy; Boehringer Ingelheim: Consultancy; GlaxoSmithKline: Consultancy; Daiichi Sankyo: Consultancy; Leo Pharma: Consultancy; Thrombogenics: Consultancy; Pfizer: Consultancy. Wells: BMS/Pfizer: Research Funding; Pfizer: Honoraria; Bayer Schering Pharma: Honoraria; Boehringer Ingelheim: Honoraria; Bayer HealthCare Pharmaceuticals: Honoraria; Biomerieux: Honoraria. Pap: Bayer Pharma AG: Employment. Lensing: Bayer Pharma AG: Employment.

*signifies non-member of ASH